Evidence map›Paper›PMID 40956542›Full record

ReviewDrug delivery and translational research2025

Toward a harmonized regulatory framework for 3D-printed pharmaceutical products: the role of critical feedstock materials and process parameters.

Riyad F Alzhrani, Rawan A Fitaihi, Majed A Majrashi, Yu Zhang, Mohammed Maniruzzaman

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Riyad F AlzhraniDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia. rfalzahrani@ksu.edu.sa.
Rawan A FitaihiDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Majed A MajrashiBioengineering Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Yu ZhangPharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA. yuzhang@olemiss.edu.ORCID 0000-0002-8925-2284
Mohammed ManiruzzamanPharmaceutical Engineering and 3D Printing (PharmE3D) Lab, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA. mmaniruz@olemiss.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The commercialization of additive manufacturing (AM) in pharmaceuticals manufacturing has attracted significant attention for its potential to produce customized products. However, the process is slow and hindered by the lack of designated regulatory guidelines tailored to 3D-printed pharmaceutical products (3DPPs). The 3D-printing technology has paved the way for personalized medicine, enabled treatment of rare genetic disorders, and offered many other possibilities for patients. Despite the US Food and Drug Administration (FDA) approval of Spritam

Indexed as

Printing, Three-DimensionalTechnology, PharmaceuticalHumansPharmaceutical PreparationsUnited StatesUnited States Food and Drug AdministrationPharmaceutical Preparations3D-printing technologyAdditive manufacturingPersonalized medicinePoint-of-careQuality controlRegulatory frameworkSpritam®

Identifiers

PMID40956542
PMCPMC12619793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.